Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT06589414 (DAMeGe) for Solid Tumours is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Reintegrating a Systematic Review Consultation With the General Practitioner After the Cancer Diagnosis Has Been Announced Into the Complex Cancer Patient Pathway: Feasibility Study (DAMeGe) 171
Clinical Trial NCT06589414 (DAMeGe) is an interventional study for Solid Tumours that is active, not recruiting. It started on 8 January 2025 with plans to enroll 171 participants. Led by Institut Claudius Regaud, it is expected to complete by 1 January 2027. The latest data from ClinicalTrials.gov was last updated on 10 February 2026.
Brief Summary
This is a prospective, multicentric, regional study designed to assess the feasibility of setting up a summary consultation with a general practitioner (GP) to complement the consultation for the announcement of a cancer diagnosis.
171 patients will be included in the study.
Each patient will be followed for 6 months.
Official Title
Reintegrating a Systematic Review Consultation With the General Practitioner After the Cancer Diagnosis Has Been Announced Into the Complex Cancer Patient Pathway: Feasibility Study
Conditions
Solid TumoursOther Study IDs
- DAMeGe
- 24 GENE 07
- ID RCB Number: 2024-A00415-42 (Other Identifier) (ANSM)
NCT ID Number
Start Date (Actual)
2025-01-08
Last Update Posted
2026-02-10
Completion Date (Estimated)
2027-01
Enrollment (Estimated)
171
Study Type
Interventional
PHASE
N/A
Status
Active, not recruiting
Keywords
Solid Tumours
Announcement system
General practitioner
Announcement system
General practitioner
Primary Purpose
Health Services Research
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
OtherDAMeGe protocol | Patient care according to the DAMeGe protocol (organisation of a summary consultation with the GP) A summary consultation with the patient's general practitioner (GP) will take place within 15 days of the consultation to announce the cancer diagnosis. This patient-general practitioner consultation will complement the initial consultation.
At the end of the summary consultation, the patient's satisfaction and that of the GP will be assessed using satisfaction questionnaires.
In addition, patients will be asked to...Show More |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
The ratio between the number of patients who attended the summary consultation with the general practitioner within 15 days of being diagnosed with cancer in the referral care centre and the total number of patients included in the study. | 21 months after the start of the study |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
The reasons why the summary consultation with the GP did not take place within 15 days of the consultation to announce the cancer diagnosis. | It will be assessed for each patient included in the study in conjunction with the patients or GPs: patient refusal, GP refusal, cancelled or postponed by the patient, cancelled or postponed by the GP, out of time (\>15 days), other reason. | 21 months after the start of the study |
The type of consultations carried out with the GP (physical consultations, teleconsultations or home visits) will be presented as follows, using standard descriptive statistics. | 21 months after the start of the study | |
The number of cancellations of consultations with GPs will be presented as follows, using standard descriptive statistics. | 21 months after the start of the study | |
The number of postponed consultations with the GP will be presented as follows, using standard descriptive statistics. | 21 months after the start of the study | |
The overall compliance will be presented as follows, using standard descriptive statistics. | 21 months after the start of the study | |
The participation will be assessed. | All ratios complementary to the main criterion will be collected and analysed (the number of patients who received the offer to participate in the systematic consultation, the number of patients actually included). | 18 months after the start of the study |
The socio-demographic characteristics of the patients included will be described and analysed. | 21 months after the start of the study | |
The rate of patients with a change in management between the treatment proposed at the RCP (Multidisciplinary Consultation Meeting) and that carried out in the centre. | It will be presented in the following format: number, percentage and 95% confidence interval (exact binomial distribution). | 6 months for each patient |
The number of hospital admissions and unscheduled consultations at the referral centre during the 6 months of follow-up will be assessed for each patient included in the study. | 6 months for each patient | |
The satisfaction of patients included in the study and of GPs whose patients take part in the study. | It will be assessed using questionnaires. Responses to the questions will be based on a Likert scale of 1 to 4: 'Completely satisfactory', 'Somewhat satisfactory', 'Somewhat unsatisfactory', 'Not at all satisfactory'. | 21 months after the start of the study |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
- Age ≥ 18 years.
- Patient with a solid tumour whatever the organ.
- Patient treated in one of the participating centres as part of a system for announcing the diagnosis of a solid cancer.
- Patient undergoing cancer treatment in one of the participating centres.
- Patient with a registered general practitioner in the Occitanie region.
- Patient affiliated to a French Social Security scheme.
- Patient having signed informed consent prior to inclusion in the study and prior to any specific procedure for the study.
- Patient already included in another clinical trial concerning a care pathway.
- Patient deprived of liberty or under legal protection (curatorship and guardianship, safeguard of justice).
- Pregnant or breast-feeding woman.
Institut Claudius RegaudLigue contre le cancer, FranceNo contact data.
5 Study Locations in 1 Countries
CH Auch, Auch, France
CH Carcassonne, Carcassonne, 11000, France
CHU Larrey, Toulouse, France
CHU Rangueil, Toulouse, France
Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France